Analysts’ Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CytomX Therapeutics (CTMX – Research Report), BiomX (PHGE – Research Report) and Moderna (MRNA – Research Report).

CytomX Therapeutics (CTMX)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on CytomX Therapeutics today. The company’s shares closed last Thursday at $1.39.

According to TipRanks.com, Kapoor is ranked 0 out of 5 stars with an average return of -26.6% and a 17.3% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Reneo Pharmaceuticals, and Carisma Therapeutics.

Currently, the analyst consensus on CytomX Therapeutics is a Hold with an average price target of $2.64.

See the top stocks recommended by analysts >>

BiomX (PHGE)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BiomX, with a price target of $7.00. The company’s shares closed last Thursday at $0.26.

According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.5% and a 27.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Cadrenal Therapeutics, Inc., and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BiomX with a $5.50 average price target, representing a 1639.4% upside. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $4.00 price target.

Moderna (MRNA)

J.P. Morgan analyst Jessica Fye maintained a Hold rating on Moderna today and set a price target of $90.00. The company’s shares closed last Thursday at $77.70, close to its 52-week low of $62.55.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 6.4% and a 51.2% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Deciphera Pharmaceuticals.

Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $118.27, which is a 48.5% upside from current levels. In a report issued on November 28, Canaccord Genuity also initiated coverage with a Hold rating on the stock with a $82.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTMX:

• CytomX Therapeutics price target raised to $3 from $2 at Wedbush
• CytomX Therapeutics reports Q3 EPS 4c, consensus (19c)
• CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
• CTMX Earnings this Week: How Will it Perform?
• CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference